Real-life use of remdesivir-containing regimens in COVID-19: a retrospective case-control study.
COVID-19
antiviral therapy
lymphopenia
real-life study
remdesivir
Journal
Le infezioni in medicina
ISSN: 2532-8689
Titre abrégé: Infez Med
Pays: Italy
ID NLM: 9613961
Informations de publication
Date de publication:
2022
2022
Historique:
received:
08
02
2022
accepted:
18
04
2022
pubmed:
14
6
2022
medline:
14
6
2022
entrez:
13
6
2022
Statut:
epublish
Résumé
Remdesivir (REM) has shown potent antiviral activity We conducted a retrospective, single-center, case-control (1:1) study including hospitalized patients with confirmed SARS-CoV-2 infection. Cases were patients treated with remdesivir for 5 days, controls were patients not receiving remdesivir. A total of 192 patients (96 cases and 96 controls) were included in the study. Patients receiving remdesivir had a lower rate of ICU admission and need for OTI than controls, whereas no difference between cases and controls were observed as for mortality rate. However, at multivariable analysis remdesivir was not associated with ICU admission neither with OTI. Instead, presence of haematological malignancies, lower duration of symptoms, higher severity of infection and low lymphocytes count at admission were independently associated with in-hospital mortality. In patients treated with remdesivir a low albumin value and duration of lymphopenia were significantly associated with mortality. Our real-life study showed that therapy with remdesivir did not have impact on either ICU admission, need for OTI or in-hospital mortality.
Sections du résumé
Background
UNASSIGNED
Remdesivir (REM) has shown potent antiviral activity
Methods
UNASSIGNED
We conducted a retrospective, single-center, case-control (1:1) study including hospitalized patients with confirmed SARS-CoV-2 infection. Cases were patients treated with remdesivir for 5 days, controls were patients not receiving remdesivir.
Results
UNASSIGNED
A total of 192 patients (96 cases and 96 controls) were included in the study. Patients receiving remdesivir had a lower rate of ICU admission and need for OTI than controls, whereas no difference between cases and controls were observed as for mortality rate. However, at multivariable analysis remdesivir was not associated with ICU admission neither with OTI. Instead, presence of haematological malignancies, lower duration of symptoms, higher severity of infection and low lymphocytes count at admission were independently associated with in-hospital mortality. In patients treated with remdesivir a low albumin value and duration of lymphopenia were significantly associated with mortality.
Conclusions
UNASSIGNED
Our real-life study showed that therapy with remdesivir did not have impact on either ICU admission, need for OTI or in-hospital mortality.
Identifiants
pubmed: 35693052
doi: 10.53854/liim-3002-6
pii: 1124-9390_30_2_2022_211-222
pmc: PMC9177180
doi:
Types de publication
Journal Article
Langues
eng
Pagination
211-222Informations de copyright
Copyright © 2016 - 2022 InfezMed.
Déclaration de conflit d'intérêts
Conflict of interest The authors declare that there are no conflicts of interest.